MX2022001027A - Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. - Google Patents
Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.Info
- Publication number
- MX2022001027A MX2022001027A MX2022001027A MX2022001027A MX2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr
- antibody
- biaspecific
- treating
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878977P | 2019-07-26 | 2019-07-26 | |
| PCT/KR2020/009870 WO2021020845A1 (en) | 2019-07-26 | 2020-07-27 | Anti-egfr/anti-4-1bb bispecific antibody and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001027A true MX2022001027A (es) | 2022-04-18 |
Family
ID=74189704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001027A MX2022001027A (es) | 2019-07-26 | 2020-07-27 | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12168690B2 (https=) |
| EP (1) | EP4004053A4 (https=) |
| JP (2) | JP7738545B2 (https=) |
| KR (1) | KR20220038767A (https=) |
| CN (2) | CN118221825A (https=) |
| AU (1) | AU2020320349A1 (https=) |
| BR (1) | BR112022001329A2 (https=) |
| CA (1) | CA3147420A1 (https=) |
| MX (1) | MX2022001027A (https=) |
| WO (1) | WO2021020845A1 (https=) |
| ZA (1) | ZA202200905B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211147A1 (es) | 2019-08-12 | 2021-06-28 | I Mab Biopharma Us Ltd | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| US20250320309A1 (en) * | 2021-11-25 | 2025-10-16 | Shenghe (China) Biopharmaceutical Co., Ltd. | Bispecific antigen binding protein |
| JP2025512915A (ja) * | 2022-04-07 | 2025-04-22 | ユハン コーポレーション | Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物 |
| JP2025542406A (ja) * | 2022-12-30 | 2025-12-25 | アブクロン・インコーポレイテッド | Ｃｄ１３７に特異的に結合するアフィボディ及びその用途 |
| KR20240164748A (ko) * | 2023-05-12 | 2024-11-20 | 앱클론(주) | 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체 |
| KR102927129B1 (ko) | 2025-03-18 | 2026-02-11 | 이트너스 주식회사 | 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2185770T3 (es) * | 1995-04-08 | 2003-05-01 | Lg Chemical Ltd | Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce. |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| AU2006211037B2 (en) | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| SI2073842T1 (sl) * | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| DK2699598T3 (en) * | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
| JP6539275B2 (ja) * | 2013-08-16 | 2019-07-03 | メモリアル スローン ケタリング キャンサー センター | 選択的ｇｒｐ９４阻害剤およびその使用 |
| SG11201704741PA (en) * | 2014-12-22 | 2017-07-28 | Systimmune Inc | Bispecific tetravalent antibodies and methods of makiing and using thereof |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| FI3436048T3 (fi) | 2016-03-31 | 2025-09-15 | Biontech Us Inc | Neoantigeeneja ja niiden käyttömenetelmiä |
| AU2017252233A1 (en) * | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| SG11202000503QA (en) * | 2017-07-20 | 2020-02-27 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| WO2019129644A1 (en) * | 2017-12-28 | 2019-07-04 | Julius-Maximilians-Universität Würzburg | TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) |
| CN119798453A (zh) * | 2018-11-13 | 2025-04-11 | Jn生物科学有限责任公司 | 激活免疫细胞的双特异性抗体 |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| PE20211147A1 (es) * | 2019-08-12 | 2021-06-28 | I Mab Biopharma Us Ltd | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso |
| CA3169943A1 (en) * | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
-
2020
- 2020-07-27 US US16/939,472 patent/US12168690B2/en active Active
- 2020-07-27 CN CN202410360186.5A patent/CN118221825A/zh active Pending
- 2020-07-27 BR BR112022001329A patent/BR112022001329A2/pt unknown
- 2020-07-27 WO PCT/KR2020/009870 patent/WO2021020845A1/en not_active Ceased
- 2020-07-27 JP JP2022504629A patent/JP7738545B2/ja active Active
- 2020-07-27 EP EP20848658.9A patent/EP4004053A4/en active Pending
- 2020-07-27 CA CA3147420A patent/CA3147420A1/en active Pending
- 2020-07-27 MX MX2022001027A patent/MX2022001027A/es unknown
- 2020-07-27 CN CN202080053851.6A patent/CN114450306B/zh active Active
- 2020-07-27 KR KR1020227006641A patent/KR20220038767A/ko active Pending
- 2020-07-27 AU AU2020320349A patent/AU2020320349A1/en active Pending
-
2022
- 2022-01-19 ZA ZA2022/00905A patent/ZA202200905B/en unknown
-
2024
- 2024-11-04 US US18/935,875 patent/US20250066487A1/en active Pending
-
2025
- 2025-09-02 JP JP2025145010A patent/JP2026004296A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022542670A (ja) | 2022-10-06 |
| CN118221825A (zh) | 2024-06-21 |
| JP2026004296A (ja) | 2026-01-14 |
| KR20220038767A (ko) | 2022-03-29 |
| CA3147420A1 (en) | 2021-02-04 |
| AU2020320349A1 (en) | 2022-02-17 |
| US20250066487A1 (en) | 2025-02-27 |
| CN114450306A (zh) | 2022-05-06 |
| JP7738545B2 (ja) | 2025-09-12 |
| US20210024638A1 (en) | 2021-01-28 |
| EP4004053A4 (en) | 2023-10-18 |
| CN114450306B (zh) | 2024-04-05 |
| US12168690B2 (en) | 2024-12-17 |
| ZA202200905B (en) | 2023-11-29 |
| BR112022001329A2 (pt) | 2022-03-22 |
| EP4004053A1 (en) | 2022-06-01 |
| WO2021020845A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001027A (es) | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. | |
| MX2022001022A (es) | Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo. | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CO2022005077A2 (es) | Compuestos moduladores de glp-1r | |
| CL2021000458A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359) | |
| FI4067387T3 (fi) | Bispesifinen anti-pd-1-anti-vegfa -vasta-aine, farmaseuttinen koostumus ja sen käyttö | |
| NZ795271A (en) | Antibody-pyrrolobenzodiazepine derivative conjugate | |
| MX2019013858A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| UY38353A (es) | Inhibición de integrina alfavbeta6 | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| IL285923A (en) | Compositions, methods, and kits for delivery of polyribonucleotides | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| EA202092000A1 (ru) | Ингибиторы димеризации egfr и их использование | |
| ZA202211405B (en) | Anti-cd73-anti-pd-1 bispecific antibody and use thereof | |
| BR112015032718A2 (pt) | composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos | |
| MX2024012294A (es) | RECEPTORES DE TGF-ß Y MÉTODOS DE USO | |
| BR112022008558A2 (pt) | Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| WO2018009507A8 (en) | COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| MX2024002261A (es) | Molecula de union de fap/cd40 y uso medicinal de la misma. | |
| ZA202309150B (en) | Antibody against nkp46 and application of antibody | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. |